Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...

Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the second quarter of 2025. The dividend will be paid on June 6, 2025, to all stockholders of ...

In a report released on March 2, David Risinger from Leerink Partners maintained a Hold rating on Amgen (AMGN – Research Report). The company’s ...

Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

In this article, we will look at the 11 Best Undervalued Stocks to Invest in Now.

UK initiative to harness big biological data sets and look deeper into how the human body works and malfunctions ...

South Korea-based Celltrion today announced that the US Food and Drug Administration (FDA) has approved Stoboclo and Osenvelt ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...